GPC2 MAY BE AN IMMUNOTHERAPEUTIC TARGET IN HIGH-RISK NEUROBLASTOMA AMER ASSOC CANCER RESEARCH September 22, 2017 Bosse, KR, P Raman, Z Zhu, M Lane, D Martinez, and S Heitzeneder Summary
